CAMBRIDGE, Mass., Oct. 28 /PRNewswire-FirstCall/ -- 3DM, Inc., a
Cambridge-based developer of synthetic biomaterials, has raised $1.7 million
in a first round of venture capital from Technology Directors, Inc., and other
investors. The funding will accelerate 3DM's clinical development of its lead
product, PuraMatrix(TM) synthetic peptide hydrogels for use in orthopedic
applications ranging from bone fill, to spinal fusion, to implant coatings, to
drug delivery. The Company has successfully completed pre-clinical safety and
efficacy testing of PuraMatrix in animal studies and plans to submit its bone
fill indication to the FDA early in 2005. Human clinical trials for other
orthopedic applications will occur later in 2005.
The funding comes on the heels of a successful product launch with BD
Biosciences, establishing 3DM's PuraMatrix line as an enabling nanotechnology
biomaterial for next generation cell culture and in vivo research and
bioproduction. Concurrent with the launch, R&D Magazine recently awarded
PuraMatrix its 42nd annual R&D 100 Prize as one of the most significant new
products to impact life science and medical research, a prestigious award held
by the likes of Taxol and the nicotine patch.
"In the last 12 months, 3DM management and its world-class scientific
founding team have established PuraMatrix as one of the best-selling synthetic
scaffolds for in vitro and in vivo drug discovery research world wide." stated
John Maki, Managing Director of Technology Directors Inc. "The combination of
BD Bioscience partnership, multiple industry collaborations and 3DM's own
aggressive clinical development program promises to establish PuraMatrix as
the next standard in biocompatible scaffolds for medical device and drug
The funding adds two experienced venture investors to 3DM's Board of
Directors. John Maki, Managing Director of Technology Directors, Inc. and
previously an investor with Audax Group and Bain Capital, was founding
investor or lead in the re-capitalizations of over 15 companies, including
Physio Control, Wesley Jessen Visioncare, Large Scale Biology, and DeNovis,
among other companies. Adam Kirsch was a founder and remains a Special
Limited Partner of Bain Capital, where he served on the boards of numerous
private and public companies including Dade Diagnostics, Blue Ridge
Pharmaceuticals, and Nutraceutical International.
"In addition to adding two terrific venture investors to our Board, this
funding will accelerate clinical development of PuraMatrix gels as a component
of next generation medical implants, enhancing healthy tissue ingrowth and
regeneration," said Zen Chu, 3DM's President and co-founder. "In addition to
orthopedic device applications, PuraMatrix enhances performance of devices for
cardiac, neurological, wound healing and drug delivery applications. 3DM is
collaborating with premier medical device companies to demonstrate
PuraMatrix's utility across each of these areas."
PuraMatrix Synthetic Peptide Hydrogels are smart polymers, self-assembling
in cell culture or in vivo to create biocompatible nanofiber scaffolds to
facilitate healthy cell growth and tissue regeneration. PuraMatrix is
currently in animal testing for orthopedics, cardiac and other medical device
and drug delivery applications. PuraMatrix is used by leading pharmaceutical,
biotechnology and academic laboratories and has been featured in over twenty
premier scientific journal publications.
About 3DM Inc.
3DM is a privately-held specialty biomaterials and medical device company
headquartered in Cambridge, Massachusetts. The patented technology,
exclusively licensed from Massachusetts Institute of Technology, was pioneered
through the work and expertise of Drs. Shuguang Zhang, Alan Grodzinsky, Robert
Langer, Alexander Rich, Carlos Semino and Lisa Spirio.
Zen Chu or Jennifer Gray
President MacDougall BioCommunications
SOURCE 3DM Inc.